The field of biopsy devices is on the cusp of transformation, driven by technological advancements that promise more accurate and minimally invasive diagnostic procedures. Innovations in medical technology, especially in precision medicine and minimally invasive techniques, are reshaping biopsy devices, prioritizing patient comfort and reducing the risks inherent in traditional biopsy methods. Artificial intelligence and machine learning are poised to revolutionize data analysis, enhancing diagnostic precision.
According to the latest report by MarketsandMarkets, the biopsy devices market is projected to witness substantial growth, soaring from an estimated $6.6 billion in 2023 to an anticipated $12.6 billion by 2028, marking a noteworthy CAGR of 14.0% during this period.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=132886515
The market’s expansion is primarily fueled by the creation of more accurate and less invasive biopsy instruments, mitigating patient discomfort and accelerating recovery. The needle-based biopsy instruments segment is projected to experience the most significant growth in the forecast period, leading the charge in technological advancements.
Segmentation by application reveals a robust outlook for breast biopsy procedures, expected to witness the highest growth rate during the forecast period of 2023-2028. These biopsy devices play a crucial role in extracting tissue samples for diagnostic purposes across various medical specialties, including breast, bone marrow, lung, colorectal, kidney, prostate, and more.
Hospitals and specialized breast care centers dominate the market as key end-users, owing to an increasing number of patients seeking diagnostic services. Additionally, advancements in imaging technologies and screening techniques have propelled the demand for biopsy procedures, facilitating precise diagnoses and personalized treatment strategies.
The Asia Pacific region is poised to register substantial growth in the biopsy devices market. Factors such as a burgeoning patient population, expanding geriatric demographic, robust economic growth, increased disposable income, and rising healthcare expenditure provide a fertile ground for market expansion in APAC countries.
Key players such as Becton, Dickinson and Company, Devicor Medical Products (Leica Biosystems), B. Braun Melsungen AG, Cardinal Health, and Hologic, Inc., are pivotal in driving innovation within the industry. Notable recent developments include Olympus’ acquisition of Odin Medical Ltd., a cloud-AI endoscopy company, and the strategic partnership between B. Braun and REVA Medical for the distribution of Fantom Encore, a bioresorbable scaffold for coronary interventions.
Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515
As the biopsy devices market continues to evolve, propelled by technological breakthroughs and strategic collaborations, it promises to significantly contribute to improved patient outcomes and the overall efficiency of healthcare systems worldwide.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441